Results 221 to 230 of about 120,626 (262)

Activation of peripheral NOP receptors reduces periorbital mechanical allodynia evoked by CGRP in mice

British Journal of Pharmacology, EarlyView.
Background and Purpose Migraine is a neurovascular disorder largely mediated by calcitonin gene‐related peptide (CGRP). This study explores the role of the nociceptin/orphanin FQ (N/OFQ)–N/OFQ receptor (NOP) system in CGRP‐induced periorbital mechanical allodynia (PMA) in mice.
Chiara Sturaro, Pietro Pola, Michela Argentieri, Alessia Frezza, Matilde Marini, Francesco De Logu, Valentina Albanese, Marie Soukupova, Davide Malfacini, Nurulain T. Zaveri, Romina Nassini, Dane D. Jensen, Pierangelo Geppetti, Girolamo Calò, Chiara Ruzza   +14 more
wiley   +1 more source

Managing headache in primary care: choosing therapies that treat the whole patient. [PDF]

Fam Med Community Health
Burroughs BT.
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Multimodal Pharmacologic Strategies for Chronic Cancer Pain: A Systematic Review. [PDF]

Cureus
Thirza SQ, Squire A, Berman R, Ahamed A.
europepmc   +1 more source

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade, Nathan Morris, Diana E. Sepulveda, Alonso Cortez‐Resendiz, Christopher Brandl, Jennifer E. Lausch, Mariya Starostina, Nicholas M. Graziane   +7 more
wiley   +1 more source

Impact of treatment duration on the effectiveness of opioid analgesia: a systematic review and meta-analysis. [PDF]

Br J Gen Pract
Froentjes LS, Barrington CA, Craig RA, Morcos M, Wedman DM, Korowynk CS, Kelmer MD, Campbell FN, Garrison SR.   +8 more
europepmc   +1 more source

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

British Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman, Christopher J. Black, Andrea Shin, Daniel Keszthelyi   +3 more
wiley   +1 more source

Multimodal Pain Management in Emergency Medicine: A Narrative Review. [PDF]

Medeni Med J
Al B, Turkmen F.
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Sublingual Administration for Pain Control: Pharmacology, Clinical Applications and Future Directions. [PDF]

CNS Drugs
Koushik SS, Gritsenko K, Binda DD, Daybell IS, Hill NS, Raghavan J, Borukh E, Smith BB, Kraus M, Shaparin N.   +9 more
europepmc   +1 more source